Pricing Log in Create free account
Friday 6 November 2026 Export OMCL’s income statement to Excel — free account

Omnicell, Inc.

OMCL Healthcare Health Information Services

Omnicell, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 6.53% from fiscal 2024.

Revenue
−0.89%
EPS
+100.5%
Free cash flow
+42.6%
Total debt
+0.73%

Quarter to September 2026, against a year earlier

37.35 0.68 −1.79%
Market cap
$1.7B
P/E
39.0×
Fwd P/E
32.9×
Dividend yield
—
F-score
7/9
Altman Z
2.69
Beneish M
−2.85
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 1.91
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 2 1 1 1 — 2 — 1 1 — — —
Insider Ownership 3.99%

Capital & Financial Ratios $m

Size
Market Cap 1,730.00
Revenue ttm 1,243.92
Net income ttm 44.67
Free cash flow ttm 132.73
Net debt Q (146.35)
Valuation
P/E 39.04 (above 35: high)
Forward P/E 32.90
Price / sales 1.40
Forward P/S Powerpack
Price / FCF 13.10
Price / book 1.35
Financial health
Current ratio Q 1.66 (at or above 1.5: strong)
Debt / equity Q 0.13 (at or below 0.5: strong)
Interest coverage Q (23.45)
Growth
Revenue growth Q −0.89% (below 0%: shrinking)
Operating income growth Q +81.14% (above 0%: growing)
EPS, this year +53.32% (at or above 15%: strong)
EPS, next year A −19.12% (below 0%: weak)
Revenue, next year A +3.64%
EPS, past 5 yrs −44.21% (below 0%: weak)
EPS, next 5 yrs A +11.70%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.4×, against a ten-year median of 2.6×; over the ten years it ranged from 1.1× in 2024 to 7.3× in 2021.
P/E against its own 10 years 4.95%
10-year low 10-year high
P/S against its own 10 years 16.21%
10-year low 10-year high
P/B against its own 10 years 16.28%
10-year low 10-year high
EV/Sales against its own 10 years 14.30%
10-year low 10-year high
EV/FCF against its own 10 years 14.59%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 468 369 197 315
Receivables 252 256 217 236
Inventory 110 89 101 98
Other 72 75 132 84
928 815 680 784
2023 2024 2025 Q'26
Payables 45 52 44 61
ST’ Debt — 174 — —
Other — — — —
368 596 477 474

Compound Annual Growth %

10y 5y 3y
Sales 9.35% 5.84% (2.94%)
Cash Flow 12.71% (7.29%) 17.85%
Earnings (23.72%) (42.34%) (28.64%)
Book Value 11.84% 4.95% 2.91%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.42 Actual 0.58

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.47 0.40 Miss by 0.07
Q1 FY26 0.33 0.55 Beat by 0.22
Q2 FY26 0.48 0.94 Beat by 0.46
Q3 FY26 0.42 0.58 Beat by 0.16
Q4 FY26 0.27 — Reports 4 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.25 0.52 0.24 — —
’25 (0.15) 0.12 0.12 (0.05) 0.04
’24 (0.34) 0.08 0.19 0.34 0.27
’23 (0.33) 0.08 0.12 (0.32) (0.45)
’22 0.17 0.20 0.37 (0.64) 0.12
’21 0.30 0.43 0.61 0.28 1.62
’20 0.26 (0.10) 0.20 0.37 0.74
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 310 312 308 — —
’25 270 291 311 314 1,185
’24 246 277 282 307 1,112
’23 291 299 299 259 1,147
’22 319 331 348 298 1,296
’21 252 273 296 311 1,132
’20 230 200 214 249 892
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 55 68 33 — —
’25 26 43 28 30 127
’24 50 59 23 56 188
’23 13 73 57 38 181
’22 (16) (10) 21 82 78
’21 57 72 43 60 232
’20 25 48 37 76 186
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 39 56 20 — —
’25 10 27 14 18 69
’24 38 45 9 43 135
’23 (1) 58 43 26 126
’22 (31) (22) 5 65 17
’21 44 58 27 43 173
’20 11 28 27 65 131
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 696 713 787 897 892 1,132 1,296 1,147 1,112 1,185 1,244 +6.1% 1,228 1,265 1,305 +3.3%
Gross margin, % 45.56 44.71 47.29 48.71 46.32 49.00 45.45 43.31 42.35 42.49 45.14 (3.1) pt
EBT 13 5 36 74 29 66 (2) (20) 26 11 67 (1.5%)
EBT margin, % 1.86 0.63 4.52 8.24 3.29 5.83 (0.19) (1.75) 2.30 0.96 5.41 (0.9) pt
Net income 10 31 38 61 32 78 6 (20) 13 2 45 (15.9%)
Per share, $
Per share, $ Revenue 19.25 19.01 20.06 21.63 20.95 26.04 29.19 25.37 24.15 25.78 27.10 +3.3%
Earnings 0.27 0.81 0.96 1.48 0.76 1.79 0.13 (0.45) 0.27 0.04 0.97 (19.1%)
Cash flow 1.38 0.66 2.65 3.50 4.36 5.33 1.75 4.01 4.08 2.77 4.06 +8.0%
Capex (0.81) (0.81) (1.39) (1.49) (1.29) (1.34) (1.37) (1.22) (1.15) (1.26) (1.17) +5.1%
Free cash flow 0.57 (0.15) 1.26 2.01 3.08 3.99 0.38 2.79 2.93 1.51 2.89 +11.3%
Book value 11.94 14.79 17.32 20.39 22.72 26.38 25.45 26.30 27.00 26.80 28.70 +9.4%
Shares, m 36 37 39 41 43 43 44 45 46 46 46 +2.7%
Valuation, ×
Valuation, × P/E 128.36 86.77 63.79 55.22 155.87 100.80 368.14 0.00 164.89 1,132.50 39.04 225.6
P/S 1.79 2.60 3.05 3.78 5.73 6.93 1.77 1.47 1.84 1.76 1.40 3.1
P/B 2.88 3.35 3.54 4.01 5.28 6.84 2.02 1.42 1.65 1.69 1.35 3.3
EV/Sales 2.07 2.85 3.16 3.70 5.72 7.09 1.96 1.57 1.82 1.88 1.42 3.2
EV/FCF 69.61 (356.25) 50.19 39.85 38.96 46.25 148.79 14.28 14.98 32.12 13.32 9.9
Cash, $m
Cash, $m Operating cash flow 50 25 104 145 186 232 78 181 188 127 186 +11.0%
Capex (29) (31) (54) (62) (55) (58) (61) (55) (53) (58) (53) +7.9%
Free cash flow 21 (6) 50 83 131 173 17 126 135 69 133 +14.4%
Balance, $m
Balance, $m Working capital 134 147 193 246 553 (95) 453 560 220 203 310 +4.7%
Net debt 200 178 68 (67) (7) 179 247 102 (28) (29) (146) n/m
Shareholders’ equity 432 554 680 845 968 1,147 1,130 1,189 1,243 1,232 1,317 +12.4%
Returns, %
Returns, % ROA 1.29 3.13 3.60 5.28 2.10 3.92 0.26 (0.92) 0.58 0.10 2.23 (1.2) pt
ROIC 2.12 0.95 3.71 6.29 2.31 4.22 (0.11) (1.69) 0.02 0.27 3.45 (1.8) pt
ROE 2.34 6.19 6.12 8.05 3.55 7.36 0.50 (1.76) 1.03 0.17 0.00 (2.2) pt
People
People Employees 2,444 2,350 2,480 2,700 2,860 3,800 4,230 3,650 3,670 3,580 — +4.3%
Revenue/emp, $m 0.28 0.30 0.32 0.33 0.31 0.30 0.31 0.31 0.30 0.33 — +1.7%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 2 Nov 2026

Omnicell, Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PRVA Privia Health Group, Inc. $3.1B 88.3× 83.4× +13.19% (above 0%: growing) +83.33% (above 0%: growing) −44.35% (below 0%: shrinking) 0.00% 3.13% Compare
SDGR Schrodinger, Inc. $2.2B — (loss-making) — (loss-making) +18.72% (above 0%: growing) n/m +21.64% (above 0%: growing) 59.32% (40.52%) Compare
CERT Certara, Inc. $1.9B — (loss-making) — (loss-making) −9.29% (below 0%: shrinking) +300.00% (above 0%: growing) −12.09% (below 0%: shrinking) 66.87% 2.45% Compare
OMCL Omnicell, Inc. $1.7B 39.0× 32.9× −0.89% (below 0%: shrinking) +100.50% (above 0%: growing) +42.62% (above 0%: growing) 44.77% 4.85%
TDOC Teladoc Health, Inc. $1.7B — (loss-making) — (loss-making) −3.41% (below 0%: shrinking) n/m +11.76% (above 0%: growing) 68.56% (4.64%) Compare
GDRX GoodRx Holdings, Inc. $1.2B 65.7× 46.0× −1.31% (below 0%: shrinking) −25.00% (below 0%: shrinking) +112.45% (above 0%: growing) 89.52% 11.79% Compare
OMDA Omada Health, Inc. $1.2B 267× 156× +43.12% (above 0%: growing) n/m +45.71% (above 0%: growing) 72.62% 4.04% Compare
HSTM HealthStream, Inc. $905.6M 42.0× 45.4× +8.94% (above 0%: growing) −8.90% (below 0%: shrinking) −4.80% (below 0%: shrinking) 63.98% 7.91% Compare
PHR Phreesia, Inc. $788.9M 74.4× 40.2× +10.41% (above 0%: growing) +200.00% (above 0%: growing) +43.51% (above 0%: growing) 66.64% 5.88% Compare
Median of peers $1.5B 74.4× 46.0× +9.68% +83.33% +16.70% 66.76% 3.59%

All 44 Health Information Services stocks →

Pay and ownership Proxy statement filed 13 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 7.53m 2.41m 37.74
2024 8.17m 14.85m 37.09
2023 11.02m 4.28m 31.35
2022 7.90m (13.26m) 42.01
2021 8.44m 23.01m 150.34

Ownership

Directors and executive officers, together 2.92%
BlackRock, Inc. 15.72%
Dimensional Fund Advisors LP 5.20%
Millennium Management LLC 5.03%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Omnicell, Inc. (OMCL) Latest News

2 Nov

Impact 3 · · StockStory
Impact 3 · · StockStory

30 Oct

Impact 3 · · Simply Wall St.

29 Oct

Impact 4 · · MarketBeat
Impact 4 · · The Motley Fool transcript
Impact 3 · · Moby
Impact 3 · · Zacks
Impact 3 · · StockStory
Impact 3 · · Associated Press
Impact 3 · · Zacks

28 Oct

Impact 3 · · StockStory

22 Oct

Impact 3 · · StockStory

13 Oct

Impact 4 · · Zacks

7 Oct

Impact 3 · · Simply Wall St.

5 Oct

Impact 3 · · StockStory

22 Sep

Impact 4 · · Simply Wall St.

21 Sep

Impact 3 · · StockStory

3 Sep

Impact 4 · · PR Newswire

13 Aug

Impact 3 ·

12 Aug

Impact 4 ·

3 Aug

Impact 3 ·
Impact 3 ·

31 Jul

Impact 4 ·

30 Jul

Impact 4 · transcript
Impact 3 · · MarketBeat transcript
Impact 3 ·
Impact 3 ·
Impact 3 ·

29 Jul

Impact 4 ·

21 Jul

Impact 3 ·
stockrow.com/OMCL · Data as of Nov 2, 2026 · For information only; not investment advice. · © 2026 stockrow.com